We are analyzing https://link.springer.com/article/10.1007/bf02789239.

Title:
Preclinical models for the evaluation of targeted therapies of metastatic disease | Cell Biochemistry and Biophysics
Description:
It has been estimated that approx 60–70% of cancer patients harbor overt or subclinical metastases at diagnosis, and it is the eradication of such systemic disease that largely determines survival. Preclinical tumor model systems employed to evaluate potential new treatment strategies should aim to represent the process and patterns of metastasis of their clinical counterparts as closely as possible. Severe combined immune-deficient (SCID) andnu/nu mice have been extensively used as hosts for the growth of human tumor cell lines and in some cases fresh tumor material. However, in most instances the resulting neoplasms fail to metastasize, and the aberrant immune systems of such animals has limited their use mainly to passive therapies of localized disease. Recently, the development of specially selected tumor variants and the use of appropriate orthotopic sites for implantation has provided several models in which dissemination can be demonstrated. Where the gene coding for a potential target antigen has been cloned, and where its overexpression or mutation is associated with malignancy (e.g., c-erbB-2, H-ras), transgenic mice may yield tumors that will develop in these immunocompetent hosts. In some cases such tumors exhibit metastasis. A third approach is to transfect human genes of interest into appropriate rodent tumors expressing the desired metastatic phenotype. These various approaches are compared with particular reference to mammary carcinoma biology.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

google, scholar, cas, article, pubmed, cancer, eccles, cell, models, dean, disease, tumor, met, privacy, cookies, content, research, preclinical, box, metastasis, access, int, publish, search, court, mice, oncogene, usa, biol, res, rev, data, information, log, journal, biophysics, targeted, therapies, metastatic, treatment, tumors, discover, smith, med, proc, natl, acad, sci, styles, johnson,

Topics {✒️}

mammary carcinoma biology transgenic mice month download article/chapter andnu/nu mice preclinical models severe combined immune-deficient tumors exhibit metastasis breast cancer res full article pdf privacy choices/manage cookies scid aberrant immune systems targeted therapies check access instant access metastatic disease published transfect human genes cellular immune mechanisms cancer research european economic area scope submit manuscript largely determines survival resulting neoplasms fail potential target antigen related subjects van den berg conditions privacy policy rodent tumors expressing desired metastatic phenotype van de velde cell biophysics 24 accepting optional cookies models main content log metastasis journal finder publish article log cancer treatment article cite article eccles metastatic disease systemic disease localized disease privacy policy personal data treatment strategies cancer res dean rights tumor microenvironment tumor dormancy

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Preclinical models for the evaluation of targeted therapies of metastatic disease
         description:It has been estimated that approx 60–70% of cancer patients harbor overt or subclinical metastases at diagnosis, and it is the eradication of such systemic disease that largely determines survival. Preclinical tumor model systems employed to evaluate potential new treatment strategies should aim to represent the process and patterns of metastasis of their clinical counterparts as closely as possible. Severe combined immune-deficient (SCID) andnu/nu mice have been extensively used as hosts for the growth of human tumor cell lines and in some cases fresh tumor material. However, in most instances the resulting neoplasms fail to metastasize, and the aberrant immune systems of such animals has limited their use mainly to passive therapies of localized disease. Recently, the development of specially selected tumor variants and the use of appropriate orthotopic sites for implantation has provided several models in which dissemination can be demonstrated. Where the gene coding for a potential target antigen has been cloned, and where its overexpression or mutation is associated with malignancy (e.g., c-erbB-2, H-ras), transgenic mice may yield tumors that will develop in these immunocompetent hosts. In some cases such tumors exhibit metastasis. A third approach is to transfect human genes of interest into appropriate rodent tumors expressing the desired metastatic phenotype. These various approaches are compared with particular reference to mammary carcinoma biology.
         datePublished:
         dateModified:
         pageStart:279
         pageEnd:291
         sameAs:https://doi.org/10.1007/BF02789239
         keywords:
            Preclinical models
            monoclonal antibodies
            targeted therapy
            cancer
            metastasis
            xenografts
            transgenic mice
            SCID mice
            oncoproteins
            mammary carcinoma
            Biochemistry
            general
            Pharmacology/Toxicology
            Biotechnology
            Cell Biology
            Biological and Medical Physics
            Biophysics
         image:
         isPartOf:
            name:Cell Biophysics
            issn:
               1559-0283
               0163-4992
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Humana Press
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:S. A. Eccles
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Box
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                        type:PostalAddress
                     type:Organization
               type:Person
               name:W. Court
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Sandle
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. J. Dean
               affiliation:
                     name:Institute of Cancer Research
                     address:
                        name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Preclinical models for the evaluation of targeted therapies of metastatic disease
      description:It has been estimated that approx 60–70% of cancer patients harbor overt or subclinical metastases at diagnosis, and it is the eradication of such systemic disease that largely determines survival. Preclinical tumor model systems employed to evaluate potential new treatment strategies should aim to represent the process and patterns of metastasis of their clinical counterparts as closely as possible. Severe combined immune-deficient (SCID) andnu/nu mice have been extensively used as hosts for the growth of human tumor cell lines and in some cases fresh tumor material. However, in most instances the resulting neoplasms fail to metastasize, and the aberrant immune systems of such animals has limited their use mainly to passive therapies of localized disease. Recently, the development of specially selected tumor variants and the use of appropriate orthotopic sites for implantation has provided several models in which dissemination can be demonstrated. Where the gene coding for a potential target antigen has been cloned, and where its overexpression or mutation is associated with malignancy (e.g., c-erbB-2, H-ras), transgenic mice may yield tumors that will develop in these immunocompetent hosts. In some cases such tumors exhibit metastasis. A third approach is to transfect human genes of interest into appropriate rodent tumors expressing the desired metastatic phenotype. These various approaches are compared with particular reference to mammary carcinoma biology.
      datePublished:
      dateModified:
      pageStart:279
      pageEnd:291
      sameAs:https://doi.org/10.1007/BF02789239
      keywords:
         Preclinical models
         monoclonal antibodies
         targeted therapy
         cancer
         metastasis
         xenografts
         transgenic mice
         SCID mice
         oncoproteins
         mammary carcinoma
         Biochemistry
         general
         Pharmacology/Toxicology
         Biotechnology
         Cell Biology
         Biological and Medical Physics
         Biophysics
      image:
      isPartOf:
         name:Cell Biophysics
         issn:
            1559-0283
            0163-4992
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Humana Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:S. A. Eccles
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Box
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                     type:PostalAddress
                  type:Organization
            type:Person
            name:W. Court
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Sandle
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. J. Dean
            affiliation:
                  name:Institute of Cancer Research
                  address:
                     name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cell Biophysics
      issn:
         1559-0283
         0163-4992
      volumeNumber:24
Organization:
      name:Humana Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institute of Cancer Research
      address:
         name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
         type:PostalAddress
      name:Institute of Cancer Research
      address:
         name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:S. A. Eccles
      affiliation:
            name:Institute of Cancer Research
            address:
               name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
               type:PostalAddress
            type:Organization
      name:G. Box
      affiliation:
            name:Institute of Cancer Research
            address:
               name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
               type:PostalAddress
            type:Organization
      name:W. Court
      affiliation:
            name:Institute of Cancer Research
            address:
               name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
               type:PostalAddress
            type:Organization
      name:J. Sandle
      affiliation:
            name:Institute of Cancer Research
            address:
               name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
               type:PostalAddress
            type:Organization
      name:C. J. Dean
      affiliation:
            name:Institute of Cancer Research
            address:
               name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
      name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
      name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
      name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
      name:Section of Immunology, Haddow Laboratories, Institute of Cancer Research, Sutton, UK125
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(112)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.02s.

LINK . SPRINGER . COM {}